Buscar
Sangamo Therapeutics Inc
SGMOAñadir a la lista de seguimiento
0.178USD
0.0000.00%
Cierre 05/15, 16:00（ET）Cotizaciones retrasadas 15 min
55.93MCap. mercado
PérdidaP/E TTM
Más Datos de Sangamo Therapeutics Inc Compañía
Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.
Información de Sangamo Therapeutics Inc
Símbolo de cotizaciónSGMO
Nombre de la empresaSangamo Therapeutics Inc
Fecha de salida a bolsaApr 06, 2000
Director ejecutivoMacrae (Alexander D)
Número de empleados183
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 06
Dirección501 Canal Blvd.
CiudadRICHMOND
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94084
Teléfono15109706000
Sitio Webhttps://www.sangamo.com/
Símbolo de cotizaciónSGMO
Fecha de salida a bolsaApr 06, 2000
Director ejecutivoMacrae (Alexander D)
Ejecutivos de Sangamo Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Scott B. Willoughby
Mr. Scott B. Willoughby
Chief Legal Officer & Corporate Secretary
Chief Legal Officer & Corporate Secretary
572.66K
+55.96%
Dr. Gregory Davis, Ph.D.
Dr. Gregory Davis, Ph.D.
Head of Research & Technology
Head of Research & Technology
114.13K
-61.18%
Dr. Courtney Beers, Ph.D.
Dr. Courtney Beers, Ph.D.
Independent Director
Independent Director
82.65K
+7.56%
Ms. Margaret A. Horn, J.D.
Ms. Margaret A. Horn, J.D.
Independent Director
Independent Director
82.65K
+7.56%
Ms. H. Stewart Parker
Ms. H. Stewart Parker
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Alexander D. Macrae, Ph.D.
Dr. Alexander D. Macrae, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Robert F. Carey
Mr. Robert F. Carey
Independent Director
Independent Director
--
--
Dr. Karen Lesley Smith, M.D., Ph.D.
Dr. Karen Lesley Smith, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. James R. Meyers
Mr. James R. Meyers
Independent Director
Independent Director
--
--
Dr. John H. Markels, Ph.D.
Dr. John H. Markels, Ph.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Scott B. Willoughby
Mr. Scott B. Willoughby
Chief Legal Officer & Corporate Secretary
Chief Legal Officer & Corporate Secretary
572.66K
+55.96%
Dr. Gregory Davis, Ph.D.
Dr. Gregory Davis, Ph.D.
Head of Research & Technology
Head of Research & Technology
114.13K
-61.18%
Dr. Courtney Beers, Ph.D.
Dr. Courtney Beers, Ph.D.
Independent Director
Independent Director
82.65K
+7.56%
Ms. Margaret A. Horn, J.D.
Ms. Margaret A. Horn, J.D.
Independent Director
Independent Director
82.65K
+7.56%
Ms. H. Stewart Parker
Ms. H. Stewart Parker
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Alexander D. Macrae, Ph.D.
Dr. Alexander D. Macrae, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Desglose de ingresos
FY2025
FY2024
FY2023
La empresa aún no ha revelado los datos relevantes.
Por regiónUSD
Nombre
Ganancia
Proporción
United States
39.55M
0.00%
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: jue., 14 de may
Actualizado: jue., 14 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Vanguard Capital Management, LLC
3.07%
Two Sigma Investments, LP
2.20%
Renaissance Technologies LLC
2.04%
BlackRock Institutional Trust Company, N.A.
1.10%
Geode Capital Management, L.L.C.
0.93%
Otro
90.67%
Accionistas
Accionistas
Proporción
Vanguard Capital Management, LLC
3.07%
Two Sigma Investments, LP
2.20%
Renaissance Technologies LLC
2.04%
BlackRock Institutional Trust Company, N.A.
1.10%
Geode Capital Management, L.L.C.
0.93%
Otro
90.67%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
7.91%
Hedge Fund
4.86%
Investment Advisor/Hedge Fund
2.24%
Individual Investor
0.98%
Research Firm
0.95%
Corporation
0.78%
Pension Fund
0.06%
Venture Capital
0.04%
Otro
82.16%
Participación institucional
Actualizado: mié., 1 de abr
Actualizado: mié., 1 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
310
78.48M
18.95%
-38.54M
2025Q4
306
59.50M
16.66%
-53.91M
2025Q3
319
55.42M
16.47%
-39.56M
2025Q2
349
61.18M
25.54%
-60.51M
2025Q1
404
58.78M
24.86%
-65.68M
2024Q4
408
67.57M
32.39%
-54.70M
2024Q3
411
61.90M
29.72%
-75.37M
2024Q2
422
105.29M
52.02%
-52.38M
2024Q1
424
122.66M
61.96%
-20.13M
2023Q4
430
104.60M
58.76%
-36.84M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Two Sigma Investments, LP
9.12M
2.2%
+4.46M
+95.94%
Dec 31, 2025
Renaissance Technologies LLC
8.43M
2.04%
-1.75M
-17.21%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
4.54M
1.1%
-8.68K
-0.19%
Dec 31, 2025
Geode Capital Management, L.L.C.
3.87M
0.93%
+579.55K
+17.63%
Dec 31, 2025
Biogen Inc
3.25M
0.78%
-11.40M
-77.82%
Aug 14, 2024
UBS Financial Services, Inc.
1.02M
0.25%
-296.23K
-22.43%
Dec 31, 2025
Susquehanna International Group, LLP
2.14M
0.52%
-283.25K
-11.70%
Dec 31, 2025
Charles Schwab Investment Management, Inc.
1.71M
0.41%
+174.33K
+11.33%
Dec 31, 2025
Ver más
ETFs relacionados
Actualizado: mar., 2 de dic
Actualizado: mar., 2 de dic
Nombre
Proporción
Invesco NASDAQ Future Gen 200 ETF
0.62%
iShares Neuroscience and Healthcare ETF
0.28%
Global X Genomics & Biotechnology ETF
0.2%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
iShares Micro-Cap ETF
0%
ProShares Hedge Replication ETF
0%
Schwab U.S. Small-Cap ETF
0%
State Street SPDR S&P Kensho New Econ Comp ETF
0%
State Street SPDR S&P Biotech ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Ver más
Invesco NASDAQ Future Gen 200 ETF
Proporción0.62%
iShares Neuroscience and Healthcare ETF
Proporción0.28%
Global X Genomics & Biotechnology ETF
Proporción0.2%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0.02%
iShares Micro-Cap ETF
Proporción0%
ProShares Hedge Replication ETF
Proporción0%
Schwab U.S. Small-Cap ETF
Proporción0%
State Street SPDR S&P Kensho New Econ Comp ETF
Proporción0%
State Street SPDR S&P Biotech ETF
Proporción0%
Global X Russell 2000 Covered Call ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
